Kessler Topaz Meltzer & Check, LLP is investigating Medline Inc. for potential securities law violations on behalf of investors who purchased Medline Class A common stock and suffered losses. The investigation follows an FDA warning letter published on June 2, 2026, citing significant violations of Current Good Manufacturing Practice regulations, including failure to thoroughly investigate discrepancies and microbial contamination incidents. Medline's stock fell over 7% after the FDA news, and then dropped over 12% on August 5, 2026, after the company reported second quarter results and lowered its full-year adjusted EBITDA guidance.
